Evidence map›Paper›PMID 31077344›Full record

ArticleBritish journal of pharmacology2019

Strain-selective efficacy of sacubitril/valsartan on carotid fibrosis in response to injury in two inbred mouse strains.

Vyacheslav A Korshunov, Breandan Quinn, Abrar Faiyaz, Rifat Ahmed, Mark P Sowden, Marvin M Doyley, Bradford C Berk

Open access · bronzeAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Natriuretic Peptide Receptor 2 Locus Contributes to Carotid Remodeling.Journal of the American Heart Association · 2020
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Vyacheslav A KorshunovAab Cardiovascular Research Institute, Department of Medicine, University of Rochester, Rochester, New York.ORCID 0000-0002-3809-2639
Breandan QuinnAab Cardiovascular Research Institute, Department of Medicine, University of Rochester, Rochester, New York.
Abrar FaiyazDepartment of Electrical and Computer Engineering, Hajim School of Engineering and Applied Sciences, University of Rochester, Rochester, New York.
Rifat AhmedDepartment of Electrical and Computer Engineering, Hajim School of Engineering and Applied Sciences, University of Rochester, Rochester, New York.
Mark P SowdenAab Cardiovascular Research Institute, Department of Medicine, University of Rochester, Rochester, New York.
Marvin M DoyleyDepartment of Electrical and Computer Engineering, Hajim School of Engineering and Applied Sciences, University of Rochester, Rochester, New York.
Bradford C BerkAab Cardiovascular Research Institute, Department of Medicine, University of Rochester, Rochester, New York.
Rochester Institute of Technology · USUniversity of Rochester · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeSacubitril/valsartan (Sac/val) is more effective than valsartan in lowering BP and mortality in patients with heart failure. Here, we proposed that Sac/val treatment would be more effective in preventing pathological vascular remodelling in 129X1/SvJ (129X1), than in C57BL/6J (B6) inbred mice. EXPERIMENTAL APPROACH: Sac/val (60 mg·kg KEY

resultsSac/val was more effective than valsartan in lowering BP in 129X1 compared with B6 mice. Liver expression of CYP2C9 and plasma cGMP levels were similar across treatments. A reduction in carotid thickening after prophylactic treatment with valsartan or Sac/val also resulted in significant arterial shrinkage in B6 mice. In 129X1 mice, Sac/val and prophylactic treatment with valsartan had no effect on carotid thickening but preserved carotid size. BP lowering significantly correlated with a decline in carotid stiffness (R CONCLUSION AND IMPLICATIONS: These results underscore the importance of the genetic background in the efficacy of the Sac/val on vascular fibrosis.

Indexed as

AminobutyratesAngiotensin Receptor AntagonistsAnimalsBiphenyl CompoundsBlood PressureCarotid ArteriesCarotid Artery InjuriesDrug CombinationsFibrosisMaleMice, Inbred StrainsSpecies SpecificityTetrazolesTranscriptomeValsartanVascular StiffnessAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug Combinationssacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartan

Identifiers

PMID31077344
PMCPMC6609549
OpenAlexW2944518937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.